Clinical Trial Update: Establishing Cardiovascular Biomarkers to Define Preferred Lantus® Use [Phase 4]

View source ↗

Summary

Phase 4 study examining cardiovascular biomarkers to define preferred use of Lantus (insulin glargine) in insulin-requiring Type 2 diabetes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Lantus (insulin glargine)

Snippet

Sponsor: ikfe-CRO GmbH | Conditions: Insulin-requiring Type 2 Diabetes Mellitus | Phase 4 | Status: UNKNOWN